FDA approves IL | 合法藥品大搜索

2019年4月23日—Risankizumab,aninterleukin-23inhibitor,hasbeenapprovedbytheFoodandDrugAdministrationfortreatingmoderatetosevereplaque ...

Risankizumab, an interleukin-23 inhibitor, has been approved by the Food and Drug Administration for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, the manufacturer announced on April 23.

Risankizumab[1] selectively inhibits interleukin-23 (IL-23), a key inflammatory protein, by binding to its p19 subunit. The drug is administered at a dose of 150 mg, in two subcutaneous injections, every 12 weeks, after starting doses at weeks 0 and 4. It will be available in early May, according to an AbbVie press release announcing the approval.

The approval was based in part on data from two phase 3, 2-year studies, In UltIMMA-1[2] and UltIMMA-2[3], at 16 weeks, 75% of risankizumab patients in both studies achieved a Psoriasis Area and Severity Index (PASI 90), compared with 5% and 2% of those on placebo, respectively. These results were published in 2018 (Lancet. 2018 Aug 25;392[10148]:650-61[4]).

At 1 year, 82% ...

risankizumab | 合法藥品大搜索

at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS. Avoid use of live vaccines in patients treated with SKYRIZI. (7.1). See ... Read More

Drugs@FDA: FDA | 合法藥品大搜索

2019年4月23日 — SKYRIZI, RISANKIZUMAB-RZAA, 75MG/0.83ML, INJECTABLE;INJECTION, Prescription, None, No, No. Showing 1 to 1 of 1 entries ... Read More

761105Orig1s000 | 合法藥品大搜索

2019年4月23日 — Table 5 Risankizumab Drug Substance, Formulation and Presentation Used in ... FDA approved drugs for the treatment of moderate to severe. Read More

Reference ID | 合法藥品大搜索

SKYRIZI® (risankizumab-rzaa) injection, for subcutaneous use. Initial U.S. Approval: 2019. RECENT MAJOR CHANGES. Dosage and Administration (2). 04/2021. Read More

Skyrizi (risankizumab | 合法藥品大搜索

Skyrizi FDA Approval History ... Company: AbbVie Inc. ... Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis. Read More

Risankizumab Submitted for Regulatory Approval to FDA ... | 合法藥品大搜索

2021年4月7日 — Most recently, risankizumab 150 mg was FDA-approved in April 2019 for the treatment of moderate to severe plaque psoriasis in adult patients who ... Read More

Skyrizi (Risankizumab | 合法藥品大搜索

由 L Fala 著作 — Risankizumab-rzaa FDA Approved for Plaque Psoriasis ... On April 23, 2019, risankizumab-rzaa (Skyrizi; AbbVie), an IL-23 antagonist, was approved by the US Food ... Read More

AbbVie Submits Regulatory Applications for SKYRIZI ... | 合法藥品大搜索

2021年4月7日 — ... for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA ... applications seeking approval for SKYRIZI® (risankizumab-rzaa, ... Read More

Reference ID | 合法藥品大搜索

SKYRIZI® (risankizumab-rzaa) injection, for subcutaneous use. Initial U.S. Approval: 2019. INDICATIONS AND USAGE. SKYRIZI is an interleukin-23 antagonist ... Read More

FDA approves IL | 合法藥品大搜索

2019年4月23日 — Risankizumab, an interleukin-23 inhibitor, has been approved by the Food and Drug Administration for treating moderate to severe plaque ... Read More

相關資訊整理